Abstract
Abstract only
- Title
- Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial
- Creators
- Eric Pujade-Lourraine - Hôtel-Dieu de ParisNicoletta Colombo - European Institute of OncologyMary L. Disis - University of WashingtonKeiichi Fujiwara - Saitama Medical UniversityJonathan A. Ledermann - University College LondonMansoor Raza Mirza - Copenhagen University HospitalGary Edward Richardson - Cabrini HospitalJ. Thaddeus Beck - Highlands Oncology GroupStephanie Gaillard - Duke Medical CenterPatricia Haney - PfizerMichael Shnaidman - PfizerAlexei Morozov - PfizerBradley J. Monk - University of Arizona
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.TPS5600-TPS5600
- Identifiers
- 991005968876202656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article